open access

Vol 86, No 6 (2015)
ARTICLES
Get Citation

Evaluation of erythromycin concentration in the umbilical artery serum

Magdalena Bulska, Piotr Szcześniak, Anna Stepowicz, Aleksandra wasiak, Agnieszka Pięta-Dolińska, Przemysław Oszukowski, Daria Orszulak-Michalska
DOI: 10.17772/gp/2402
·
Ginekol Pol 2015;86(6).

open access

Vol 86, No 6 (2015)
ARTICLES

Abstract

Objectives: The aim of the study was to investigate the effectiveness of erythromycin in preventing intrauterine infection caused by group B streptococcus (GBS). Material and methods: The study included 20 pregnant women with GBS-positive screening or whose laboratory screening was not available, who delivered between April 17, 2013 and July 22, 2013. The women were given 600 mg of erythromycin intravenously. After delivery, blood was drawn in parallel from maternal antecubital vein and umbilical cord artery. Serum erythromycin concentrations were evaluated using enzyme-linked immunosorbent assay (ELISA) kit. Statistical analysis for measurable and non-measurable characteristics were performed, correlation coefficients for each pair of variables were calculated in order to investigate the sought dependence. Results: Mean placental transfer of erythromycin was 2.04%. There was a high correlation between umbilical artery serum and maternal serum erythromycin concentration. Selected variables of mothers in the control group had no effect on serum erythromycin concentration in the umbilical artery. Conclusions: Transplacental transfer of erythromycin is limited (2.04%). Intravenous application of erythromycin at a dose of 600 mg does not allow to achieve the value of MIC50 and MIC90 for erythromycin against strains S. agalactiae in umbilical artery serum, what suggests a compromised efficacy in the treatment of intrauterine fetal infections. At the same time, the placenta seems to be an effective barrier reducing fetal exposure when this macrolide is used to treat maternal infections.

Abstract

Objectives: The aim of the study was to investigate the effectiveness of erythromycin in preventing intrauterine infection caused by group B streptococcus (GBS). Material and methods: The study included 20 pregnant women with GBS-positive screening or whose laboratory screening was not available, who delivered between April 17, 2013 and July 22, 2013. The women were given 600 mg of erythromycin intravenously. After delivery, blood was drawn in parallel from maternal antecubital vein and umbilical cord artery. Serum erythromycin concentrations were evaluated using enzyme-linked immunosorbent assay (ELISA) kit. Statistical analysis for measurable and non-measurable characteristics were performed, correlation coefficients for each pair of variables were calculated in order to investigate the sought dependence. Results: Mean placental transfer of erythromycin was 2.04%. There was a high correlation between umbilical artery serum and maternal serum erythromycin concentration. Selected variables of mothers in the control group had no effect on serum erythromycin concentration in the umbilical artery. Conclusions: Transplacental transfer of erythromycin is limited (2.04%). Intravenous application of erythromycin at a dose of 600 mg does not allow to achieve the value of MIC50 and MIC90 for erythromycin against strains S. agalactiae in umbilical artery serum, what suggests a compromised efficacy in the treatment of intrauterine fetal infections. At the same time, the placenta seems to be an effective barrier reducing fetal exposure when this macrolide is used to treat maternal infections.
Get Citation

Keywords

erythromycin / group B streptococcus infection / placental transfer /

About this article
Title

Evaluation of erythromycin concentration in the umbilical artery serum

Journal

Ginekologia Polska

Issue

Vol 86, No 6 (2015)

DOI

10.17772/gp/2402

Bibliographic record

Ginekol Pol 2015;86(6).

Keywords

erythromycin / group B streptococcus infection / placental transfer /

Authors

Magdalena Bulska
Piotr Szcześniak
Anna Stepowicz
Aleksandra wasiak
Agnieszka Pięta-Dolińska
Przemysław Oszukowski
Daria Orszulak-Michalska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl